Novo Nordisk’s 27% drop was market overreaction, analysts say 0 23.12.2024 14:14 MarketWatch.com Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health’s analysts said Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
